United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints
Go back to United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints| United Therapeutics Corp (NASDAQ: UTHR) | Delayed: 547.25 -8.66 (1.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $555.91 | 52 Week High | $164.04 | |||
| Open | $556.31 | 52 Week Low | $97.52 | |||
| Day High | $556.45 | P/E | 100.05 | |||
| Day Low | $543.82 | EPS | $5.47 | |||
| Volume | 326,596 | |||||
